Claims
- 1. A compound comprising a structure of the following Formula I, II, III or IV covalently bound to a solid surface:
- 2. A compound of claim 1 wherein R, each R″, R1, R2 and R3 are each independently selected from the group of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted carbocyclic aryl, an optionally substituted mononucleotide, an optionally substituted polynucleotide, or an optionally substituted heteroaromatic or heteroalicyclic group preferably having from 1 to 3 separate or fused ring and 1 to 3 N, O or S atoms.
- 3. A compound of claim 1 wherein B is optionally substituted adenine, optionally substituted thymidine, optionally substituted cytosine or an optionally substituted guanine.
- 4. A compound of claims 1 wherein the support is a reaction body.
- 5. A compound of claim 1 wherein the substrate is a microarray substrate.
- 6. A compound of claim 1 wherein the substrate contains a plurality of oligonucleotides covalently linked to the substrate.
- 7. A compound of claim 1 wherein the compound is covalently bound to the substrate via an interposed linker.
- 8. A compound of claim 7 wherein the linker comprises two or more carbon-carbon unsaturated groups.
- 9. A compound of claim 7 wherein the linker comprises an aromatic group.
- 10. A compound of claim 7 wherein the linker has a hydroxy or amino substituent.
- 11. A compound of claim 7 wherein the linker has hydroxy and alkylhydroxy substituents.
- 12. A compound of claim 1 wherein the plurality of physphoramidate compounds are each independently selected from the following Formulae V and VI:
- 13. A library of compounds having a structure of the following Formula I, II, III or IV:
- 14. A library of claim 13 wherein R, R″, R1, R2 and R3 are each independently selected from the group of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted carbocyclic aryl, an optionally substituted mononucleotide, an optionally substituted polynucleotide, or an optionally substituted heteroaromatic or heteroalicyclic group preferably having from 1 to 3 separate or fused ring and 1 to 3 N, O or S atoms.
- 15. A library of claim 13 wherein B is optionally substituted adenine, optionally substituted thymidine, optionally substituted cytosine or an optinally substituted guanine.
- 16. A library of claim 13 wherein the library comprises dinucleotide compounds.
- 17. A library of one of claim 13 wherein the library comprises trinucleotide compounds.
- 18. A library of claim 13 wherein the library comprises at least about 20 distinct compounds.
- 19. A library of claims 13 wherein the library comprises at least about 100 distinct compounds.
- 20. A library of claim 13 wherein the library comprises one or more compounds of the following Formulae V and VI:
- 21. A method for preparing a plurality of phosphoramidate compounds, comprising contacting a plurality of nucleoside reagents with one or more amines to provide a plurality of phosphoramidate compounds.
- 22. The method of claim 21 wherein the nucleoside reagents are reacted with a plurality of amines.
- 23. The method of claim 21 wherein the nucleoside reagents are covalently bound to a solid support.
- 24. The method of claims 21 wherein the plurality of phosphoramidate compounds are prepared in a single reaction sequence.
- 25. The method of claim 21 wherein the one or more amines are independently an acyclic amine, alicyclic amine or aromatic amine.
- 26. The method of claim 21 the one or more amines are independently primary or secondary amines.
- 27. The method of claims 21 wherein at least about 20 distinct phosphoramidate compounds are provided.
- 28. The method of claim 21 wherein at least about 100 distinct phosphoramidate compounds are provided.
- 29. The method of claim 21 wherein the plurality of phosphoramidate compounds are each independently selected from the following Formulae I, II, III and IV:
- 30. A method of claims 21 wherein the plurality of phosphoramidate compounds are each independently selected from the following Formulae V and VI:
- 31. A method of claim 30 wherein each R and each R3 are each independently selected from the group of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cyclialkenyl, optionally substituted carbocyclic aryl, an optionally substituted mononucleotide, an optionally substituted polynucleotide, or an optionally substituted heteroaromatic or heteroalicyclic group preferably having from 1 to 3 separate or fused ring and 1 to 3 N, O or S atoms.
- 32. A method of claim 30 wherein B1and B2 are each independently an optionally substituted adenine, optionally substituted thymidine, optionally substituted cytosine or an optionally substituted guanine.
- 33. A method of treating a subject suffering from or susceptible to a viral infection, comprising administering to the subject an effective of a compound of the following Formulae I, II, III or IV:
- 34. A method of claim 32 wherein the compound is of the following Formulae V or VI:
- 35. A method of claim 33 wherein each R and each R3 are each independently selected from the group of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted carbocyclic aryl, an optionally substituted mononucleotide, an optionally substituted polynucleotide, or an optionally substituted heteroaromatic or heteroalicyclic group preferably having from 1 to 3 separate or fused ring and 1 to 3 N, O or S atoms.
- 36. A method of claim 33 wherein B1 and B2 are each independently an optionally substituted adenine, optionally substituted thymidine, optionally substituted cytosine or an optionally substituted guanine.
- 37. A method of claim 32 wherein the subject is suffering from or susceptible to an HBV infection.
Parent Case Info
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 60/301,991, filed Jun. 29, 2001 and U.S. Provisional Patent Application No. 60/302,875, filed Jul. 2, 2001.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60301991 |
Jun 2001 |
US |
|
60302875 |
Jul 2001 |
US |